Tumour heterogeneity in the clinic
Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …
genotype variations between patients, called interpatient heterogeneity, that predict the …
EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations
E Thunnissen, L Bubendorf, M Dietel, G Elmberger… - Virchows Archiv, 2012 - Springer
In non-small cell lung cancer, epidermal growth factor receptor gene mutations and
anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the …
anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the …
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of …
NI Lindeman, PT Cagle, DL Aisner… - … of pathology & …, 2018 - meridian.allenpress.com
Context.—In 2013, an evidence-based guideline was published by the College of American
Pathologists, the International Association for the Study of Lung Cancer, and the Association …
Pathologists, the International Association for the Study of Lung Cancer, and the Association …
Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC)
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
focuses on targeted therapies and immunotherapies for metastatic NSCLC, because …
NCCN guidelines insights: non–small cell lung cancer, version 5.2018
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of
management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the …
management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the …
[HTML][HTML] Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American …
NI Lindeman, PT Cagle, MB Beasley, DA Chitale… - Journal of Thoracic …, 2013 - Elsevier
Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
Non–small cell lung cancer, version 6.2015
These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for
Non–Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in …
Non–Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in …
Non–small cell lung cancer
Most patients with non–small cell lung cancer (NSCLC) are diagnosed with advanced
cancer. These guidelines only include information about stage IV NSCLC. Patients with …
cancer. These guidelines only include information about stage IV NSCLC. Patients with …
Analysis of receptor tyrosine kinase ROS1-positive tumors in non–small cell lung cancer: identification of a FIG-ROS1 fusion
VM Rimkunas, KE Crosby, D Li, Y Hu, ME Kelly… - Clinical Cancer …, 2012 - AACR
Purpose: To deepen our understanding of mutant ROS1 expression, localization, and
frequency in non–small cell lung cancer (NSCLC), we developed a highly specific and …
frequency in non–small cell lung cancer (NSCLC), we developed a highly specific and …
Crizotinib for the Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in …
SHI Ou, CH Bartlett, M Mino-Kenudson, J Cui… - The …, 2012 - academic.oup.com
Abstract Crizotinib, an ALK/MET/ROS1 inhibitor, was approved by the US Food and Drug
Administration for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small …
Administration for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small …